Adirondack Trust Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Adirondack Trust Company’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Sell	375 -9	-2%	-$6.13K	0.07%	139
2026 Q1	$297K	Buy	384 +4	+1%	+$3.06K	0.1%	120
2025 Q4	$293K	Sell	380 -7	-2%	-$4.75K	0.1%	120
2025 Q3	$218K	Sell	387 -13	-3%	-$7.35K	0.07%	137
2025 Q2	$210K	Sell	400 -51	-11%	-$28.5K	0.08%	133
2025 Q1	$286K	Buy	451 +18	+4%	+$12.4K	0.11%	118
2024 Q4	$308K	Buy	433 +2	+0.5%	+$1.68K	0.12%	113
2024 Q3	$453K	Buy	431 +10	+2%	+$11.1K	0.17%	99
2024 Q2	$442K	Sell	421 -1	-0.2%	-$969	0.18%	97
2024 Q1	$406K	Sell	422 -16	-4%	-$15.2K	0.17%	102
2023 Q4	$423K	Sell	438 -22	-5%	-$18.1K	0.18%	96
2023 Q3	$379K	Hold	460	–	–	0.19%	90
2023 Q2	$341K	Sell	460 -10	-2%	-$7.71K	0.16%	108
2023 Q1	$386K	Sell	470 -7	-1%	-$5.28K	0.2%	96
2022 Q4	$344K	Hold	477	–	–	0.18%	106
2022 Q3	$329K	Buy	477 +27	+6%	+$17K	0.18%	99
2022 Q2	$266K	Buy	450 +57	+15%	+$37.1K	0.14%	104
2022 Q1	$274K	Buy	393 +127	+48%	+$80.3K	0.13%	106
2021 Q4	$168K	Buy	266 +4	+2%	+$2.46K	0.08%	127
2021 Q3	$168K	Buy	262 +11	+4%	+$6.83K	0.08%	127
2021 Q2	$140K	Hold	251	–	–	0.07%	133
2021 Q1	$119K	Buy	251 +140	+126%	+$68.2K	0.06%	139
2020 Q4	$56K	Buy	111 +3	+3%	+$1.62K	0.03%	164
2020 Q3	$60K	Hold	108	–	–	0.04%	156
2020 Q2	$68K	Hold	108	–	–	0.05%	152
2020 Q1	$53K	Buy	108 +5	+5%	+$2.06K	0.04%	149
2019 Q4	$35K	Sell	103 -28	-21%	-$9.42K	0.02%	189
2019 Q3	$36K	Hold	131	–	–	0.03%	182
2019 Q2	$41K	Hold	131	–	–	0.03%	179
2019 Q1	$45K	Hold	131	–	–	0.03%	166
2018 Q4	$49K	Sell	131 -9	-6%	-$3.29K	0.04%	158
2018 Q3	$57K	Buy	140 +5	+4%	+$1.9K	0.04%	160
2018 Q2	$47K	Hold	135	–	–	0.03%	163
2018 Q1	$41K	Buy	135 +35	+35%	+$12.2K	0.03%	167
2017 Q4	$38K	Hold	100	–	–	0.03%	166
2017 Q3	$45K	Hold	100	–	–	0.04%	160
2017 Q2	$49K	Sell	100 -15	-13%	-$6.56K	0.04%	157
2017 Q1	$45K	Sell	115 -55	-32%	-$20.4K	0.03%	165
2016 Q4	$62K	Hold	170	–	–	0.04%	150
2016 Q3	$68K	Buy	170 +55	+48%	+$22.1K	0.05%	149
2016 Q2	$40K	Hold	115	–	–	0.03%	192
2016 Q1	$41K	Hold	115	–	–	0.03%	172
2015 Q4	$48K	Sell	115 -5	-4%	-$2.71K	0.04%	159
2015 Q3	$56K	Buy	120 +5	+4%	+$2.69K	0.05%	143
2015 Q2	$59K	Buy	115 +5	+5%	+$2.44K	0.04%	148
2015 Q1	$50K	Buy	110 +5	+5%	+$2.12K	0.04%	160
2014 Q4	$43K	Buy	105 +5	+5%	+$1.97K	0.03%	167
2014 Q3	$36K	Buy	100 +10	+11%	+$3.35K	0.03%	172
2014 Q2	$25K	Buy	90 +40	+80%	+$11.9K	0.02%	195
2014 Q1	$15K	Buy	+50	New	+$15.4K	0.01%	213

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Adirondack Trust Company's REGN Position: Q2 2026 in Review

Adirondack Trust Company reduced its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q2 2026, selling an estimated $6.13K and leaving 375 shares worth $234K. The position accounts for 0.07% of the portfolio, ranked #139.

Adirondack Trust Company first reported a position in REGN in Q1 2014 and has held it in 50 quarters since. The position peaked at $453K in Q3 2024. 293 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Adirondack Trust Company held 375 shares of Regeneron Pharmaceuticals worth $234K as of Q2 2026.
Adirondack Trust Company sold 9 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.13K.
Regeneron Pharmaceuticals made up 0.07% of Adirondack Trust Company's portfolio in Q2 2026, its #139 holding.
Adirondack Trust Company first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 50 quarters since.
Adirondack Trust Company's Regeneron Pharmaceuticals position peaked at $453K in Q3 2024.
293 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Adirondack Trust Company's 13F filing for Q2 2026, filed 16 Jul 2026.